trial · primary record
Sacituzumab tirumotecan
Colorectal Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 220 |
| Primary completion | 2029-10-16 |
| Primary endpoint | Number of Participants Who Experience a Dose-limiting Toxicity (DLT) |
| Registry ID | NCT06428409 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:39.587Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06428409
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Sacituzumab Tirumotecan · compound